|By Marketwired .||
|June 13, 2014 07:42 PM EDT||
LONDON, ONTARIO -- (Marketwired) -- 06/13/14 -- Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX VENTURE:COT), the bioinformatics and accelerated drug discovery company, is pleased to announce that SeeThruEquity, LLC ("SeeThruEquity") of New York, NY has initiated research coverage of COTI.
The initial research report is dated June 12, 2014 and is available from SeeThruEquity by contacting them at http://www.seethruequity.com.
SeeThruEquity is a New York, NY based equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. SeeThruEquity does not conduct any investment banking or commission based business and the research reports it prepares are not paid for by the issuers being reported upon and are unbiased. SeeThruEquity is approved to contribute its research to Thomson Reuters One (First Call), CapitalIQ, FactSet, and Zacks and distributes its research to its database of opt-in investors. SeeThruEquity also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.
SeeThruEquity was started in March 2011. Since then, the company has initiated coverage on numerous NYSE, NASDAQ, TSX, and OTC companies in a variety of industries including technology, health care, consumer, energy and special situations and have hosted several investor conferences in New York City.
About Critical Outcome Technologies Inc.
COTI is a leading-edge bioinformatics company specializing in accelerating the discovery and development of small molecules - dramatically reducing the time and cost to bring new drugs to market. COTI's proprietary artificial intelligence system, CHEMSAS®, utilizes a series of predictive computer models to identify compounds with a high probability of being successfully developed from disease specific drug discovery through chemical optimization and preclinical testing. These compounds are targeted for a variety of diseases, particularly those for which current treatments are either lacking or ineffective.
For more information, visit www.criticaloutcome.com.
Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.